Page 7 - 2020 ASCO-GU Canadian Ambassador Program
P. 7
CONTENT – PROSTATE CANCER
TOPICS
Abstract 14: Comparative quality of life in patients randomized contemporaneously to
docetaxel or abiraterone in the STAMPEDE trial
Abstract 15: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant
metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.
Abstract 16: Pain response and health-related quality of life (HRQL) analysis in patients
with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ)
versus abiraterone or enzalutamide in the CARD study.
Abstract 17: The effect of deep AR suppression with enzalutamide or apalutamide on
endogenous glucocorticoids: Implications for adverse effects and development of
combination therapies.
Abstract 325: Eight-year outcomes of a phase III randomized trial of conventional versus
hypofractionated high-dose intensity modulated radiotherapy for prostate cancer
(CRUK/06/016): Update from the CHHiP Trial.
